Eugia Pharma Specialities Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Eugia Pharma Specialities Limited Pharmaceutical Export Portfolio Dataset — 49 Products, $170.1M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Eugia Pharma Specialities Limited — Pharmaceutical Exporter Profile (2026) | 49 Products, $170.1M Trade | TransData Nexus

Eugia Pharma Specialities Limited

Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $170.1M Total Trade · DGFT Verified

Eugia Pharma Specialities Limited is an Indian pharmaceutical exporter with a total trade value of $170.1M across 49 products in 14 therapeutic categories. Based on 3,898 verified export shipments from Indian Customs (DGFT) records, Eugia Pharma Specialities Limited is the #1 Indian exporter in 4 products including Ertapenem, Sodium, Tamoxifen. Top exports include Ertapenem ($26.9M), Meropenem ($17.1M), Pantoprazole ($15.4M).

Eugia Pharma Specialities Limited — Export Portfolio & Destination Treemap

Eugia Pharma Specialities Limited pharmaceutical export portfolio — 49 products across 14 therapeutic categories. Source: Indian Customs (DGFT).

Who is Eugia Pharma Specialities Limited? — Company Overview & Market Position

Eugia Pharma Specialities Limited, incorporated on April 17, 2013, is a public limited company based in Hyderabad, Telangana, India. The company specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Its Corporate Identification Number (CIN) is U24297TG2013PLC087048.

As of March 31, 2025, Eugia Pharma reported an authorized capital of ₹800 crore and a paid-up capital of ₹621.01 crore. The company's registered office is located at Plot No.2, Maitrivihar, Ameerpet, Hyderabad, Telangana 500038, India.

What Does Eugia Pharma Specialities Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ertapenem$26.9M 2Meropenem$17.1M

Product Portfolio — Top 30 by Export Value

Eugia Pharma Specialities Limited exports 49 pharmaceutical products across 14 therapeutic categories. Market leader (#1 exporter) in 4 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ertapenem	Advanced Antibiotics	$26.9M	537	24.6%	1
2	Meropenem	Advanced Antibiotics	$17.1M	341	7.6%	2
3	Pantoprazole	Gastrointestinal	$15.4M	308	1.2%	3
4	Sodium	Nutritional Supplements	$13.6M	271	3.8%	1
5	Lenalidomide	Advanced Oncology	$9.4M	189	1.1%	2
6	Tamoxifen	Advanced Oncology	$6.7M	182	45.3%	1
7	Gemcitabine	Oncology	$5.9M	188	12.7%	2
8	Irinotecan	Oncology	$4.4M	88	10.7%	3
9	Imatinib	Advanced Oncology	$4.1M	82	14.0%	2
10	Capecitabine	Advanced Oncology	$4.0M	80	4.5%	4
11	Linezolid	Advanced Antibiotics	$3.8M	91	10.1%	4
12	Acetaminophen	Analgesics & Antipyretics	$3.7M	83	1.6%	8
13	Amino	Nutritional Supplements	$3.7M	83	1.1%	13
14	Anastrozole	Advanced Oncology	$3.5M	116	3.2%	3
15	Bortezomib	Advanced Oncology	$3.5M	69	15.8%	2
16	Carboplatin	Oncology	$3.3M	66	4.7%	2
17	Dexamethasone	Corticosteroids	$3.2M	64	1.8%	8
18	Acyclovir	Antivirals	$2.9M	58	2.3%	5
19	Methotrexate	Immunosuppressants	$2.9M	58	8.3%	2
20	Piperacillin	Advanced Antibiotics	$2.9M	58	3.3%	5
21	Azithromycin	Antibiotics	$2.8M	56	1.5%	11
22	Pemetrexed	Advanced Oncology	$2.4M	48	8.3%	2
23	Paclitaxel	Oncology	$2.1M	88	2.5%	10
24	Vancomycin	Antibiotics	$2.0M	40	2.2%	4
25	Vati	Ayurvedic & Herbal Products	$2.0M	40	7.6%	3
26	Moxifloxacin	Advanced Antibiotics	$1.9M	39	5.9%	3
27	Letrozole	Advanced Oncology	$1.8M	119	5.7%	4
28	Methylprednisolone	Corticosteroids	$1.6M	32	5.5%	3
29	Prednisolone	Respiratory	$1.6M	32	1.7%	8
30	Doxorubicin	Oncology	$1.4M	98	2.1%	7

Eugia Pharma Specialities Limited exports 49 pharmaceutical products across 14 therapeutic categories with a total export value of $170.1M. The company is the #1 Indian exporter in 4 products: Ertapenem, Sodium, Tamoxifen. The top category is Advanced Antibiotics (31.0% of portfolio), followed by Advanced Oncology (23.2%), reflecting a diversified portfolio where the top 5 products account for only 48.4% of total value.

Showing top 30 of 49 products. Contact us for complete data.

Eugia Pharma Specialities Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Eugia Pharma operates multiple manufacturing facilities in India, specializing in the production of finished pharmaceutical formulations. These facilities are equipped to handle a diverse range of dosage forms, including tablets, capsules, syrups, and injections. The company's manufacturing plants are strategically located to cater to both domestic and international markets.

3Key Leadership

The leadership team at Eugia Pharma includes:

Yugandhar Puvvala: Chief Executive Officer (CEO) and Executive Director, appointed on December 27, 2021.

Madan Mohan Reddy Mettu: Director, serving since April 17, 2013.

Veerayya Chowdary Kosaraju: Director, appointed on December 1, 2021.

Santhanam Subramanian: Director, appointed on October 1, 2021.

Ragunathan Kannan: Director, appointed on December 1, 2021.

Sundari Raviprasad Pisupati: Director, appointed on December 1, 2021.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Eugia Pharma Specialities Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Eugia Pharma has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals for various products, enabling it to supply finished pharmaceutical formulations to these regions. Eugia Pharma's commitment to quality and compliance with international standards has facilitated its market access in these territories.

2Emerging Markets

Eugia Pharma has expanded its footprint in emerging markets across Africa, Latin America, and Southeast Asia. The company's products have been prequalified by the World Health Organization (WHO), enhancing their acceptance and availability in these regions. This prequalification underscores Eugia Pharma's dedication to meeting global health standards and addressing the pharmaceutical needs of diverse populations.

3Geographic Strategy

Eugia Pharma's geographic strategy involves diversification across multiple regions, including both regulated and emerging markets. This approach mitigates concentration risk and positions the company to leverage growth opportunities worldwide. The strategic direction focuses on expanding market reach while maintaining a strong presence in key therapeutic areas.

Eugia Pharma Specialities Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Eugia Pharma's manufacturing facility, Unit III, located in Hyderabad, Telangana, was inspected by the U.S. Food and Drug Administration (FDA) from January 22 to February 2, 2024. The inspection identified significant violations of Current Good Manufacturing Practice (CGMP) regulations, leading to a warning letter issued on August 15, 2024. The company has acknowledged the observations and is taking corrective actions to address the issues raised.

2WHO & EU GMP

Eugia Pharma's manufacturing facilities have been prequalified by the World Health Organization (WHO), ensuring that its products meet international quality standards. Additionally, the company holds European Union Good Manufacturing Practice (EU GMP) certificates, affirming its compliance with EU regulations for pharmaceutical manufacturing. These certifications facilitate the company's access to global markets and reflect its commitment to quality assurance.

3CDSCO & Indian Regulatory

Eugia Pharma Specialities Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Eugia Pharma operates in a competitive landscape with several key players in the pharmaceutical industry. The company's focus on finished pharmaceutical formulations, including advanced antibiotics and oncology products, positions it in direct competition with other manufacturers specializing in these therapeutic areas. Market share dynamics and competitive strategies are continually evolving, requiring Eugia Pharma to adapt and innovate to maintain its market position.

2Key Differentiators

Eugia Pharma's key differentiators include its comprehensive portfolio of finished pharmaceutical formulations, with a strong emphasis on advanced antibiotics and oncology products. The company's commitment to quality, as evidenced by WHO prequalification and EU GMP certifications, enhances its reputation in the global market. Additionally, Eugia Pharma's strategic geographic diversification and focus on emerging markets provide a competitive edge in addressing diverse healthcare needs.

3Strategic Position

Eugia Pharma's current strategic direction centers on expanding its presence in both regulated and emerging markets, with a particular focus on advanced antibiotics and oncology products. The company is investing in research and development to enhance its product portfolio and address unmet medical needs. Future outlooks indicate a continued emphasis on innovation, quality assurance, and market diversification to sustain growth and competitiveness.

Buyer Due Diligence Brief — Evaluating Eugia Pharma Specialities Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Eugia Pharma has demonstrated a strong track record in pharmaceutical manufacturing, with a significant export volume of $170.1 million USD across 3,898 shipments. The company's portfolio includes 49 products across 14 therapeutic categories, indicating a diverse and consistent supply capability. Reliability indicators such as regulatory approvals, including WHO prequalification and EU GMP certifications, further attest to Eugia Pharma's commitment to quality and dependability.

2Certifications to Verify

Importers should verify the following certifications when considering Eugia Pharma as a supplier:

FDA Facility Registration: Confirm the facility's registration status with the U.S. FDA to ensure compliance with U.S. regulations.

WHO-GMP Certification: Verify the WHO Good Manufacturing Practice certification to ensure adherence to international quality standards.

Frequently Asked Questions — Eugia Pharma Specialities Limited

How many pharmaceutical products does Eugia Pharma Specialities Limited export from India?

Eugia Pharma Specialities Limited exports 49 pharmaceutical products across 14 therapeutic categories. The top exports are Ertapenem ($26.9M), Meropenem ($17.1M), Pantoprazole ($15.4M), Sodium ($13.6M), Lenalidomide ($9.4M). Total export value is $170.1M.

What is Eugia Pharma Specialities Limited's total pharmaceutical export value?

Eugia Pharma Specialities Limited's total pharmaceutical export value is $170.1M, based on 3,898 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Eugia Pharma Specialities Limited the #1 Indian exporter?

Eugia Pharma Specialities Limited is the #1 Indian exporter in 4 products: Ertapenem (24.6% market share), Sodium (3.8% market share), Tamoxifen (45.3% market share).

What therapeutic categories does Eugia Pharma Specialities Limited cover?

Eugia Pharma Specialities Limited exports across 14 therapeutic categories. The largest are Advanced Antibiotics (31.0%, 6 products), Advanced Oncology (23.2%, 17 products), Oncology (11.4%, 7 products).

Get Full Eugia Pharma Specialities Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.